Literature DB >> 23470147

A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.

Ali Emileh1, Ferit Tuzer, Herman Yeh, Muddegowda Umashankara, Diogo R M Moreira, Judith M Lalonde, Carole A Bewley, Cameron F Abrams, Irwin M Chaiken.   

Abstract

Peptide triazole (PT) entry inhibitors prevent HIV-1 infection by blocking the binding of viral gp120 to both the HIV-1 receptor and the coreceptor on target cells. Here, we used all-atom explicit solvent molecular dynamics (MD) to propose a model for the encounter complex of the peptide triazoles with gp120. Saturation transfer difference nuclear magnetic resonance (STD NMR) and single-site mutagenesis experiments were performed to test the simulation results. We found that docking of the peptide to a conserved patch of residues lining the "F43 pocket" of gp120 in a bridging sheet naïve gp120 conformation of the glycoprotein led to a stable complex. This pose prevents formation of the bridging sheet minidomain, which is required for receptor-coreceptor binding, providing a mechanistic basis for dual-site antagonism of this class of inhibitors. Burial of the peptide triazole at the gp120 inner domain-outer domain interface significantly contributed to complex stability and rationalizes the significant contribution of hydrophobic triazole groups to peptide potency. Both the simulation model and STD NMR experiments suggest that the I-X-W [where X is (2S,4S)-4-(4-phenyl-1H-1,2,3-triazol-1-yl)pyrrolidine] tripartite hydrophobic motif in the peptide is the major contributor of contacts at the gp120-PT interface. Because the model predicts that the peptide Trp side chain hydrogen bonding with gp120 S375 contributes to the stability of the PT-gp120 complex, we tested this prediction through analysis of peptide binding to gp120 mutant S375A. The results showed that a peptide triazole KR21 inhibits S375A with 20-fold less potency than WT, consistent with predictions of the model. Overall, the PT-gp120 model provides a starting point for both the rational design of higher-affinity peptide triazoles and the development of structure-minimized entry inhibitors that can trap gp120 into an inactive conformation and prevent infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23470147      PMCID: PMC3800186          DOI: 10.1021/bi400166b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  62 in total

1.  Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Authors:  Alyssa C Biorn; Simon Cocklin; Navid Madani; Zhihai Si; Tijana Ivanovic; James Samanen; Donald I Van Ryk; Ralph Pantophlet; Dennis R Burton; Ernesto Freire; Joseph Sodroski; Irwin M Chaiken
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

2.  Understanding and predicting druggability. A high-throughput method for detection of drug binding sites.

Authors:  Peter Schmidtke; Xavier Barril
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

3.  Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor.

Authors:  Simon Cocklin; Hosahudya Gopi; Bianca Querido; Manideepthi Nimmagadda; Syna Kuriakose; Claudia Cicala; Sandya Ajith; Sabine Baxter; James Arthos; Julio Martín-García; Irwin M Chaiken
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  The structural basis of peptide-protein binding strategies.

Authors:  Nir London; Dana Movshovitz-Attias; Ora Schueler-Furman
Journal:  Structure       Date:  2010-02-10       Impact factor: 5.006

5.  Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges.

Authors:  K Vanommeslaeghe; E Prabhu Raman; A D MacKerell
Journal:  J Chem Inf Model       Date:  2012-11-28       Impact factor: 4.956

6.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

7.  Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors.

Authors:  Karyn McFadden; Patricia Fletcher; Fiorella Rossi; Muddagowda Umashankara; Vanessa Pirrone; Srivats Rajagopal; Hosahudya Gopi; Fred C Krebs; Julio Martin-Garcia; Robin J Shattock; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

8.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

9.  Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.

Authors:  Hosahudya Gopi; M Umashankara; Vanessa Pirrone; Judith LaLonde; Navid Madani; Ferit Tuzer; Sabine Baxter; Isaac Zentner; Simon Cocklin; Navneet Jawanda; Shendra R Miller; Arne Schön; Jeffrey C Klein; Ernesto Freire; Fred C Krebs; Amos B Smith; Joseph Sodroski; Irwin Chaiken
Journal:  J Med Chem       Date:  2008-04-11       Impact factor: 7.446

10.  Fpocket: an open source platform for ligand pocket detection.

Authors:  Vincent Le Guilloux; Peter Schmidtke; Pierre Tuffery
Journal:  BMC Bioinformatics       Date:  2009-06-02       Impact factor: 3.169

View more
  15 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  Disulfide Sensitivity in the Env Protein Underlies Lytic Inactivation of HIV-1 by Peptide Triazole Thiols.

Authors:  Lauren D Bailey; Ramalingam Venkat Kalyana Sundaram; Huiyuan Li; Caitlin Duffy; Rachna Aneja; Arangassery Rosemary Bastian; Andrew P Holmes; Kantharaju Kamanna; Adel A Rashad; Irwin Chaiken
Journal:  ACS Chem Biol       Date:  2015-10-22       Impact factor: 5.100

3.  Peptide Triazole Inactivators of HIV-1 Utilize a Conserved Two-Cavity Binding Site at the Junction of the Inner and Outer Domains of Env gp120.

Authors:  Rachna Aneja; Adel A Rashad; Huiyuan Li; Ramalingam Venkat Kalyana Sundaram; Caitlin Duffy; Lauren D Bailey; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-04-28       Impact factor: 7.446

4.  Mechanism of multivalent nanoparticle encounter with HIV-1 for potency enhancement of peptide triazole virus inactivation.

Authors:  Arangassery Rosemary Bastian; Aakansha Nangarlia; Lauren D Bailey; Andrew Holmes; R Venkat Kalyana Sundaram; Charles Ang; Diogo R M Moreira; Kevin Freedman; Caitlin Duffy; Mark Contarino; Cameron Abrams; Michael Root; Irwin Chaiken
Journal:  J Biol Chem       Date:  2014-11-04       Impact factor: 5.157

5.  Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.

Authors:  Kriti Acharya; Adel A Rashad; Francesca Moraca; Per Johan Klasse; John P Moore; Cameron Abrams; Irwin Chaiken
Journal:  Proteins       Date:  2017-03-11

6.  Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Authors:  Irwin Chaiken; Adel A Rashad
Journal:  Future Med Chem       Date:  2015-11-24       Impact factor: 3.808

7.  Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface.

Authors:  Adel A Rashad; Li-Rui Song; Andrew P Holmes; Kriti Acharya; Shiyu Zhang; Zhi-Long Wang; Ebony Gary; Xin Xie; Vanessa Pirrone; Michele A Kutzler; Ya-Qiu Long; Irwin Chaiken
Journal:  J Med Chem       Date:  2018-06-01       Impact factor: 7.446

8.  Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.

Authors:  Arangassery Rosemary Bastian; Mark Contarino; Lauren D Bailey; Rachna Aneja; Diogo Rodrigo Magalhaes Moreira; Kevin Freedman; Karyn McFadden; Caitlin Duffy; Ali Emileh; George Leslie; Jeffrey M Jacobson; James A Hoxie; Irwin Chaiken
Journal:  Retrovirology       Date:  2013-12-13       Impact factor: 4.602

Review 9.  1,2,3-Triazoles as Biomimetics in Peptide Science.

Authors:  Naima Agouram; El Mestafa El Hadrami; Abdeslem Bentama
Journal:  Molecules       Date:  2021-05-14       Impact factor: 4.411

10.  Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy.

Authors:  Ali Emileh; Caitlin Duffy; Andrew P Holmes; Arangassery Rosemary Bastian; Rachna Aneja; Ferit Tuzer; Srivats Rajagopal; Huiyuan Li; Cameron F Abrams; Irwin M Chaiken
Journal:  Biochemistry       Date:  2014-05-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.